Analyser av Q-Linea

Q-linea (Q4 Review): Fewer contracts than expected, but KPI’s pointing in the right direction - Redeye

Redeye provides an update following Q-linea’s Q4 2025 report.

Redeye • 05 feb 07:23

Q-linea (Q4 Initial take): Lower sales and higher costs than expected - Redeye

Redeye provides an initial take following Q-linea’s Q4 2025 report.

Redeye • 04 feb 08:51

Q-linea: Rights issue outcome - Redeye

Redeye comments on the outcome of Q-linea’s rights issue and has adjusted its fair value range accordingly.

Redeye • 12 nov 2025 11:46

Q-linea: Cost efficiency program - Redeye

Redeye is positive about Q-linea’s new cost efficiency program.

Redeye • 23 okt 2025 07:14

Q-linea (Q3 Review): Sales under expectations but solid cost control - Redeye

Redeye provides an update following Q-linea’s Q3 2025 report.

Redeye • 21 okt 2025 07:28

Q-linea (Q3 Initial take): Lower sales than expected, but EBIT in line - Redeye

Redeye provides an initial take following Q-linea’s Q3 2025 report.

Redeye • 20 okt 2025 09:14

Q-linea: Ahead of the rights issue - Redeye

After announcing the proposed rights issue, we update our Base Case, including the number of shares.

Redeye • 19 sep 2025 09:00

Q-linea: Proposes a secured SEK 322m rights issue - Redeye

Q-linea proposes that a SEK 322m rights issue be secured at 85.

Redeye • 18 sep 2025 13:22

Q-linea: Two additional ASTar evaluations in the Middle East - Redeye

This adds to the initial evaluation announced by Q-linea’s regional partner earlier this year.

Redeye • 08 sep 2025 10:00

Q-linea: Improved prospects to achieve the placement target for 2025 - Redeye

The company posted a trading statement in late June.

Redeye • 10 jul 2025 10:56

Q-linea: Business insight ahead of closing in on Q2 - Redeye

Q-linea provides a business update before closing and reports its Q2 result later in July.

Redeye • 23 jun 2025 08:46

Q-linea: Improved commercial momentum - Redeye

Q-linea has improved access to growth capital and recently advanced the ASTar launch in Europe , the US and the Middle East.

Redeye • 15 apr 2025 14:52

Q-linea: Improves the commercial momentum and the ASTar contribution from recurring sales - Redeye

Q-linea achieved its objective with five ASTar contracts during Q1, supported by a much-improved pipeline, and it repeats the aim to reach 3...

Redeye • 14 apr 2025 11:02

Q-linea: Delivers on the Q1 target - Redeye

Italy is one of the largest and most dynamic market for rapid AST in Europe and Q-linea has won tender in the Naples region.

Redeye • 26 mar 2025 14:32

Q-linea: Business update and commercial targets for 2025 and 2026 - Redeye

Q-linea’s recent progress in extending the commercial network, establishing a pipeline of ASTar evaluations and access to growth capital has...

Redeye • 19 mar 2025 08:24

Q-linea Q4: Several commercial steps in the right direction - Redeye

Q-linea has improved access to growth capital and recently advanced the ASTar launch in Europe and the US with a contract and a tender.

Redeye • 03 mar 2025 10:00

Q-linea Q4: Several steps in the right direction - Redeye

Q-linea has improved access to growth capital and recently advanced the ASTar launch in Europe and the US with a contract and a tender.

Redeye • 28 feb 2025 09:50

Q-linea: Secures its second US ASTar contract ahead of Q4 - Redeye

Sales from the latest US ASTar contract are to be recorded in Q1, which is positive as it adds momentum to Q-linea’s regional targeted US la...

Redeye • 26 feb 2025 07:20

Q-linea: Some take-aways from the Belgian tender win - Redeye

ASTar was awarded the tender at Cliniques Universitaires Saint-Luc in Brussels.

Redeye • 06 feb 2025 12:38

Q-linea: A minimum of SEK 183m is committed is committed in the rights issue - Redeye

Nexttobe, existing investor Ulf Landegren, certain board members, senior executives and guarantee commitments add up to SEK 183m out of SEK ...

Redeye • 09 jan 2025 09:36

Q-linea: Commits to a rights issue and improves the prospect pipeline - Redeye

Q-linea continues enhancing the pipeline of prospects, from entering tenders to close to the final contracts in Europe and the US.

Redeye • 06 nov 2024 10:32

Q-linea: Committs to a rights issue of up to SEK 225m and improves its pipeline of prospects - Redeye

Q-linea continues improving the pipeline of prospects of various stages, from entering tenders to close to the final contracts in Europe and...

Redeye • 05 nov 2024 11:18

Q-linea: Expands the European network of distributors - Redeye

Q-linea has signed S.C. Mecro System SRL as a distributor for Romania, which is part of an attractive region for Q-linea as Romania is one o...

Redeye • 11 sep 2024 12:09

Q-linea: US progress - Redeye

The NTAP reimbursement decision is distinctly positive, and the CMS decision enables clinics to use the three-year NTAP reimbursement rate o...

Redeye • 30 aug 2024 11:27

Q-linea Q2 Update: Commercial progress and financial challenges - Redeye

Q-linea and its distribution partners continue to advance pilot and tender process activities, which are leading indicators for future sales...

Redeye • 12 jul 2024 08:28

Q-linea Q2: Reducing the OPEX base in a quarter where commercial progress are balanced by stretched liquidity - Redeye

Q-linea has reduced the OPEX by SEK 50m annually, suggesting a reduced OPEX run-rate to SEK 40-45m.

Redeye • 11 jul 2024 08:23

Q-linea: ASTar is about to secure a 3-year US reimbursement at USD 97.50 - Redeye

CMS’ NTAP recommendation is positive, and we can expect a final decision by August, followed by a good chance that the NTAP reimbursement wi...

Redeye • 12 jun 2024 10:50

Q-linea Update: Commercial progress and financial challenges - Redeye

Q-linea and its distribution partners continue to advance pilot and tender process activities, leading indicators for future sales.

Redeye • 04 jun 2024 08:04

Q-linea Q1: Commercial progress together challenges to mitigate costs and secure growth capital - Redeye

Q-linea and its distribution partners continue to advance pilot and tender process activities, which is critical as this is paramount for fu...

Redeye • 31 maj 2024 10:01

Q-linea: A US launch is in sight - Redeye

Q-linea has secured a US FDA approval, which is positive.

Redeye • 29 apr 2024 09:29

Q-linea Q4 2023 update: Increasing commercial interest with a slow sales conversion - Redeye

Q-linea is making progress, including successful tenders, commercial evaluations, study support and partner discussions for the US market.

Redeye • 04 mar 2024 10:04

Q-linea Q4 2023: Intensive period ahead of a momentous year - Redeye

Q-linea has finished 2023 and also started 2024 with plenty of action.

Redeye • 27 feb 2024 09:34

Q-linea: A new SEK 50m OPEX reduction program - Redeye

Q-linea has announced a SEK 50m OPEX reduction ahead of the announced CEO change in 2024.

Redeye • 31 jan 2024 07:25

Q-linea: Secures a public tender in Italy - Redeye

Q-linea wins a 5-year public tender with a total value of EUR 0.

Redeye • 16 jan 2024 09:01

Q-linea: The first two US ASTar placements - Redeye

Q-linea finishes 2023 on a positive note as the company has placed the first two US ASTar systems.

Redeye • 29 dec 2023 07:57

Q-linea November update: Progress ahead of commercial orders - Redeye

Q-linea is making progress, including commercial evaluations and partner discussions for the US market, and the Company are also confirming ...

Redeye • 06 nov 2023 08:11

Q-linea: Progress ahead of commercial orders - Redeye

Q-linea is making progress, including commercial evaluations and partner discussions for the US market, and the Company are also confirming ...

Redeye • 02 nov 2023 09:56

Q-linea: The Basingstoke study adds much needed commercial support - Redeye

The study presented as the first commercial evaluation of Q-linea's ASTar system in the UK (presented at the IBMS congress in Birmingham ear...

Redeye • 04 okt 2023 08:38

Q-linea: Comment on the rights issue - Redeye

The outcome of the rights issue has been announced and it includes that approximately 74% have been subscribed with and without the support ...

Redeye • 25 jul 2023 14:29

Q-linea: Building a launch platform - Redeye

Q-linea is in a transition period after the break with Thermo Fisher and in Q2 there are two delivered ASTar.

Redeye • 19 jul 2023 07:37

Q-linea: Improved European distribution - Redeye

Q-linea continues to improve the network of European distribution partners and AST'ar is now represented in five European countries includin...

Redeye • 13 jul 2023 10:04

Q-linea: A SEK 263m right issue - Redeye

A SEK 263m rights issue that is almost entirely covered without remuneration for the guarantee commitment nor the subscription undertakings.

Redeye • 02 jun 2023 12:43

Q-linea is building a launch platform during 2023 - Redeye

Q-linea is in a transition period after the break with Thermo Fisher, and in Q1 there are no reported sales.

Redeye • 08 maj 2023 12:57

Q-linea: Initial take on Q1 2023 - Redeye

Q-linea is in a transition period after the break with Thermo Fisher and in Q1 there is no reported sales.

Redeye • 04 maj 2023 09:55

Q-linea: A targeted ASTar launch strategy - Redeye

Q-linea is in the early stage of its targeted European launch strategy.

Redeye • 23 mar 2023 09:53

Q-linea: A targeted market approach with a doubled credit facility - Redeye

The go-to-market strategy is now implemented following the split with Thermo Fisher during the quarter.

Redeye • 16 feb 2023 10:51

Q-linea: A new distribution partner for the UK market - Redeye

Q-linea has signed a new UK distribution partner in Canadian Pro-Lab Diagnostics.

Redeye • 09 feb 2023 09:48

Q-Linea: Outlook after Q3 - Redeye

The Thermo Fisher divorce raise many questions and several remains after the Q3 update on the 31st October.

Redeye • 01 nov 2022 09:25

Q-linea divorces from Thermo Fisher Scientific - Redeye

Q-linea and Thermo Fisher formed the collaboration in rearly February 2020.

Redeye • 27 okt 2022 13:39

Q-linea: Q2 2022, progress with prospects and the US regulatory review - Redeye

In Q2, the first ASTar remains in the stage of expanding the lead prospect pipeline.

Redeye • 14 jul 2022 10:07

Q-linea: US submission as ASTar approaches the largest market - Redeye

Q-linea and Thermo Fisher are already launching ASTar in Europe and the FDA 510 (k) submission opens up for a potential US approval within 6...

Redeye • 09 jun 2022 15:33

Q-linea Q1 2022: Sales and commercial valuation progress - Redeye

Q-linea’s partner Thermo Fisher is launching ASTar in Europe.

Redeye • 05 maj 2022 09:55

Q-linea Q4: Early launch feedback - Redeye

Q-linea's partner Thermo Fisher is launching ASTar in Europe, and Q4 is the first quarter featuring most of the launch (as of 7th of Octobe...

Redeye • 17 feb 2022 09:33

Q-linea: Robust commercial evaluation feedback - Redeye

Q-linea's announcement regarding the commercial validation study together with the launch partner Therma Fisher is good news and well-timed ...

Redeye • 16 feb 2022 11:28

Q-linea: Q2, ASTar ready to raise - Redeye

Q-linea's Q2 confirms that the ASTar launch is underway with initial sales and deliveries to the strategic global sales partner Thermo Fisch...

Redeye • 16 jul 2021 09:13